RxDoctor Payments Data

Thomas Bumbalo, MD

Pulmonary Disease · Myrtle Beach, SCNPI 1386759488

Payments from drug & device makers

$5,362in general payments, 2019–2025

Across 175 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • GSK$705
  • Veran Medical Technologies, Inc.$427
  • Regeneron Healthcare Solutions, Inc.$297
  • Boehringer Ingelheim$283
  • Abbott$252
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$3006%
  • Travel & lodging$1,55329%
  • Food & beverage$3,26061%
  • Education$2495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,362 in reported general payments places this provider in the 55th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$161,945
Medicare patients
516
Services billed
3,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter203$217,065
Fasenra PenBenralizumab19$128,280
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$43,664
Breo ElliptaFluticasone/Vilanterol46$35,503
Spiriva HandihalerTiotropium Bromide23$23,224
Spiriva RespimatTiotropium Bromide14$10,956
SymbicortBudesonide/Formoterol Fumarate25$9,202
Albuterol Sulfate HfaAlbuterol Sulfate194$8,234
Montelukast Sodium371$6,234
Azithromycin295$5,854
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,293
Wixela InhubFluticasone Propion/Salmeterol19$2,468
Prednisone254$1,086
Ipratropium Bromide46$869
Fluticasone Propionate32$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$705$252,567249 claims
AstraZenecaBreztri Aerosphere, Symbicort$90$52,86768 claims
Boehringer IngelheimSpiriva Respimat$283$10,95614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →